brivanib alaninate

Brivanib alaninate is an orally administered, investigational small molecule prodrug. It is rapidly hydrolyzed in vivo to brivanib (BMS-540215), its active form. Brivanib acts as a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) tyrosine kinases. It selectively inhibits VEGFR-2 and FGFR signaling pathways, which are critical for tumor angiogenesis and proliferation. In preclinical models, brivanib has demonstrated broad-spectrum antitumor activity by suppressing tumor growth, reducing microvessel density, inducing apoptosis, and downregulating cell cycle regulators. Brivanib alaninate was primarily developed by Bristol Myers Squibb for the treatment of hepatocellular carcinoma (HCC), metastatic colorectal cancer (MCRC), and other solid tumors. However, it remains investigational and has no current approvals.

Other names

brivanib alaninate